Loading company
Neurogene Inc.
NGNE · Nasdaq · ·
$28.40-0.3%Sep 29 close
- 1M
- -22.4%
- 6M
- +47.2%
- 1Y
- +63.9%
- 5Y
- -81.6%
NGNE · Nasdaq · ·
$28.40-0.3%Sep 29 close
The quarter ending December 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2025 | 3 months toSep 30, 2024 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$34.5M | -$22M | -56.65% |
| Profit per share | -$1.53 | -$1.05 | -45.71% |
| Free Cash Flow | -$24.1M | -$19.6M | -22.97% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Neurogene Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Neurogene (NASDAQ: NGNE) is a clinical-stage biotechnology company focused on developing life-changing genetic medicines for people and their families impacted by devastating neurological diseases. The Company is using a biology-first approach paired with optimized delivery to develop purpose-built genetic medicines, including programs powered by its novel and proprietary EXACT™ transgene regulation technology. Neurogene is advancing its lead gene therapy program, NGN-401, as a potential best-in-class, one-time treatment for Rett syndrome.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Neurogene Inc.’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.